The role of targeted therapy in thymic carcinoma

Mridula Krishnan, Apar K. Ganti

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations


Thymic carcinoma is a rare entity and can be distinguished from benign thymomas by their aggressive nature and poor prognosis. The National Comprehensive Cancer Network guidelines recommend resection followed by adjuvant platinum-based chemotherapy for resectable tumors. However, the outcomes for metastatic or relapsed thymic carcinomas are poor with no regimen showing a consistent benefit. Moreover, the relative rarity of these tumors makes clinical trials difficult. Molecular analysis of thymomas shows a high incidence of genetic mutations and targeted therapy holds promise. We will briefly outline and review the current role of targeted therapy in thymic cancer.

Original languageEnglish (US)
Pages (from-to)1712-1718
Number of pages7
JournalJournal of Oncology Pharmacy Practice
Issue number7
StatePublished - Oct 1 2019


  • Thymic carcinoma
  • mutations
  • targeted therapy
  • thymic epithelial tumors

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)


Dive into the research topics of 'The role of targeted therapy in thymic carcinoma'. Together they form a unique fingerprint.

Cite this